Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients

Inclusion Criteria: * Subject provides written informed consent prior to initiation of any study procedures. Understands and agrees to comply with planned study procedures. * Male or non-pregnant female adult ≥18 years of age at time of enrolment. * Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR and fulfils the case criteria of COVID-19 (One or more of the following must be met in lieu of a positive PCR test: fever \[defined as a temperature ≥ 100.0°F / 37.8°C documented within 24 hr. of randomization\] , absolute and relative lymphopenia and leukopenia, new typical infiltrates in x-ray of the chest or chest CT scan \[only if obtained for clinical reasons; not required by study\], no improvement on antibiotics). * Scoring a "3" or "4" (or "5", at the Investigator's discretion) on the 7-Point Ordinal Scale (see Outcome Measures) at enrolment. Note, if scoring a "2" at screening, inclusion will be met if the patient is in the process of being hospitalized or admitted to an inpatient setting. Such a patient would be assigned a "3" at enrolment for Baseline assessment purposes. * No participation in other clinical trials according to the German Medicines Act (AMG) (3 months before) at the time of this trial. Exclusion Criteria: * ALT/AST \> 5 times the upper limit of normal. * Patients with severe hepatic impairment (defined as liver cirrhosis Child stage B or C) * Stage 4 chronic kidney disease or requiring dialysis (i.e. eGFR \< 30 ml/min) * Advanced cardiac (eg, severe heart failure \[NYHA III-IV\]) or pulmonary diseases which, in the Investigator's judgment, would not make participation appropriate. * Pregnancy or breast feeding. * Anticipated transfer to another hospital which is not a study site within 72 hours. * Known allergy or hypersensitivity to CVC or its components. * Use of medications that are contraindicated with CVC and that could not be replaced or stopped during the trial period * Administration of specified drugs which interfere with the metabolism of CVC. * Patients immediately or imminently requiring mechanical ventilation. * Patients unwilling to consent to saving and propagation of pseudonymised medical data for study reasons. * Subjects who are legally detained in an official institution. * Subjects that are unsuitable to understand or to comply with the study requirements in the opinion of the investigator. * Subjects who may be dependent on the sponsor, the investigator or the trial sites.